Image
Point-of-Care™ 301

Expanding HIV Prevention in Colorado—and Nationwide

A PEP/PrEP Training Guide for Pharmacists

Point-of-Care™ 301 Online CPE Monograph: Expanding HIV Prevention in
Colorado—and Nationwide: A PEP/PrEP Training Guide for Pharmacists

Are you seeking specific insights and suggestions as you prepare to implement postexposure prophylaxis (PEP) and preexposure prophylaxis (PrEP) in your pharmacy practice? This activity qualifies participants for 2.0 CPE credits and fulfills Colorado State Board of Pharmacy training requirements under Colorado State House Bill (HB) 20-1061. Take advantage of the Q&A Forum available at: www.PrEPforCOPharms.com

Colorado Pharmacists Society has been the key entity for Statewide Protocols in Colorado, from legislation and regulatory efforts, to creation, education and implementation of all protocols. Please see additional information about the CO PrEP/PEP protocol and additional links and educational offerings HERE.

Clinical Practice Guidelines

Guidance and resources during disruption of STD clinical services; update on STD treatment options.

Centers for Disease Control and Prevention; May 2020.

2018 quick reference guide: recommended laboratory HIV testing algorithm for serum or plasma specimens.

CDC Stacks. Centers for Disease Control and Prevention; last updated January 2018.

2015 sexually transmitted diseases treatment guidelines.

Centers for Disease Control and Prevention, 2015; last reviewed December 2020.

Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV—United States, 2016.

CDC Stacks. Centers for Disease Control and Prevention; last updated May 2018.

HIV testing.

Centers for Disease Control and Prevention; 2020.

HIV testing in retail pharmacies (training for pharmacists and pharmacy staff).

Centers for Disease Control and Prevention; 2020.

Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People.

Coleman E, et al. 7th ed. East Dundee, Illinois: World Professional Association for Transgender Health; 2012.

Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society—USA Panel.

Saag MS, et al. JAMA. 2018;320(4):379-396.

ASHP [American Society of Health-System Pharmacists] guidelines on pharmacist involvement in HIV care.

Schafer JJ, et al. Am J Health Syst Pharm. 2016;73(7):468-494.

Guidelines for prevention and treatment of opportunistic infections in adults and adolescents with HIV.

US Department of Health and Human Services; revised May 2020.

Guidelines for the use of antiretroviral agents in adults and adolescents with HIV.

US Department of Health and Human Services; last updated December 2019.

Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 update. A clinical practice guideline.

US Public Health Service. Centers for Disease Control and Prevention; 2018.

Professional Resources

American Academy of HIV Medicine; supporting the HIV care provider and the profession.

State of Colorado. House Bill 20-1061.

The enacted bill concerning pharmacists’ ability to provide HIV infection prevention medications to patients. July 13, 2020.

State of Colorado. State Board of Pharmacy. Colorado State Board of Pharmacy Statewide Protocol: Pre-exposure and post-exposure prophylaxis of HIV.

Rule 17, Appendix C. Page 182.

Pre-exposure prophylaxis (PrEP). Resources to support Colorado’s Expanded Scope of Practice for Pharmacists.

Colorado Department of Public Health & Environment (CDPHE).

Basic statistics.

Centers for Disease Control and Prevention; October 2020.

HIV in the United States by region.

Centers for Disease Control and Prevention; October 2020.

HIV and youth.

Centers for Disease Control and Prevention; May 2020.

Pre-exposure prophylaxis (PrEP).

Centers for Disease Control and Prevention; May 2020.

Taking a sexual history.

Centers for Disease Control and Prevention; April 2020.

Database of antiretroviral drug interactions.

HIV InSite. University of California, San Francisco; 2019.

PrEP to prevent HIV and promote sexual health.

New York State Department of Health AIDS Institute, Clinical Guidelines Program; February 2020.

Sexual history taking toolkit; July 2020.

TargetHIV.

Ending the HIV epidemic: ready, set, PrEP.

US Department of Health and Human Services.

Center of Excellence for Transgender Health.

Prevention Science, Department of Medicine; University of California, San Francisco; 2021.

National Clinician Consultation Center.

University of California, San Francisco; 2020.

HIV drug interactions.

University of Liverpool (website); January 2021.

Patient Resources

HIV basics.

Centers for Disease Control and Prevention; November 2020.

HIV risk reduction tool. How can I prevent getting or transmitting HIV?

Centers for Disease Control and Prevention; June 2020.

Positively Aware.

Positively Aware, created by TPAN (Test Positive Aware Network), is a source of HIV-treatment news for consumers, as well as an educational tool for HIV caregivers. The site features PrEP resources, including videos for men who have sex with men and transgender people.

Prevention for women. Resources on HIV prevention for U.S. women.

HIVE online; 2019.

HIV resources.

National Institutes of Health; September 2020.

UCSF transgender care.

University of California, San Francisco; 2019.

Suggested Readings

Emtricitabine/tenofovir alafenamide; January 2020.

AIDS Info. US Department of Health and Human Services.

Emtricitabine/tenofovir disoproxil fumarate; July 2020.

AIDS Info. US Department of Health and Human Services.

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Baeten JM, et al. N Engl J Med. 2012;367(5):399-410.

Stigma, medical mistrust, and perceived racism may affect PrEP awareness and uptake in black compared to white gay and bisexual men in Jackson, Mississippi and Boston, Massachusetts.

Cahill S, et al. AIDS Care. 2017;29(11):1351-1358.

Assessing the efficacy and feasibility of a retail pharmacy-based HIV testing program.

Collins BC, et al. 24th Conference on Retroviruses and Opportunistic Infections (CROI) 2017; February 13-17, 2017; Seattle, WA. Abstract 962.

Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.

Choopanya K, et al. Lancet. 2013;381(9883):2083-2090.

Being PrEPared – preexposure prophylaxis and HIV disparities.

Goldstein RH, et al. N Engl J Med. 2018;379(14):1293-1295.

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Grant RM, et al. N Engl J Med. 2010;363(27):2587-2599.

The phase 3 DISCOVER study: daily F/TAF or F/TDF for HIV preexposure prophylaxis.

Hare CB, et al. 26th CROI 2019; March 4-7, 2019; Seattle, WA. Abstract 104.

Lifetime risk of a diagnosis of HIV infection in the United States.

Hess KL, et al. Ann Epidemiol. 2017;27(4):238-243.

PrEParing to end the HIV epidemic—California's route as a road map for the United States.

Kazi DS, et al. N Engl J Med. 2019;381(26):2489-2491.

HPTN083 interim results: pre-exposure prophylaxis (PrEP) containing long-acting injectable cabotegravir (CAB-LA) is safe and highly effective for cisgender men and transgender women who have sex with men (MSM, TGW).

Landovitz R. 23rd International AIDS Conference. July 6-10, 2020. Oral Presentation: OAXLB01 (Enter this code in the search tool).

Community pharmacy delivered PrEP to STOP HIV transmission: an opportunity NOT to miss!

Lopez MI, et al. J Am Pharm Assoc (2003). 2020;60(4):e18-e24.

Why don't patients take their drugs? The role of communication, context and culture in patient adherence and the work of the pharmacist in HIV/AIDS.

Penn C, et al. Patient Educ Couns. 2011;83(3):310-318.

4 findings from a successful HIV PrEP program.

Ross M. Pharm Times. 2016-01-07;15:30:00.

Phase 3 randomized, controlled DISCOVER study of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV preexposure prophylaxis (PrEP): week 96 results.

Ruane P, et al. 17th European AIDS Conference (EACS); November 6-9, 2019; Basel, Switzerland. Poster PE3/16.

Interdisciplinary care team with pharmacist in a community-based HIV clinic.

Samuel O, et al. J Natl Med Assoc. 2018;110(4):378-383.

Trends in the San Francisco human immunodeficiency virus epidemic in the "Getting to Zero" era.

Scheer S, et al. Clin Infect Dis. 2018;66(7):1027-1034.

How to incorporate HIV PrEP into your practice.

Stewart J, Stekler JD. J Fam Pract. 2019;68(5):254-261.

Implementation of a community pharmacy-based pre-exposure prophylaxis service: a novel model for pre-exposure prophylaxis care.

Tung EL, et al. Sex Health. 2018;15(6):556-561.

HIV testing in community pharmacies and retail clinics: a model to expand access to screening for HIV infection.

Weidle PJ, et al. J Am Pharm Assoc. 2014; 54(5):486-492.

Activity
Expanding HIV Prevention in Colorado—and Nationwide

A PEP/PrEP Training Guide for Pharmacists

Relevant Resources

PrEP for Your Patients’ Needs

The PCPs Role in Preventing HIV

Value-Based HIV Formularies

Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care

Hepatitis C is Curable

Got it? Treat it!

Real-World Issues in HIV Prevention & Treatment

The Critical Role of the Community Pharmacist

BLOCK HIV/HCV

Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.

Evolving Models of HIV Care

Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box

Updates in HCV Screening and Treatment

Key Issues Impacting OB/GYN Practice

Clinical Issues in Chronic Liver Disease

Hot Topics in HBV, HCV, and NASH

Evolving Models of HIV Care

Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice

Assessing Your Patients for HCV and HIV

Why It Matters in OB/GYN Practice Today

HIV as a Chronic Disease

A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities

The Pursuit of Hepatitis C Elimination

How the Pharmacist Can Make a Difference

Trends in Infectious Diseases: Updates on Treatment & Prevention Strategies for HIV and HCV

Understanding the Growing Syndemic — Opioids, HCV, and HIV

Stepping Up to the Challenge

The PCP’s Role in HCV Elimination

The Changing Landscape of HIV Prevention

What the Pharmacist Needs to Know about PrEP

Evolving Models of HIV Care (Volume 3)

The Rapid ART Standard of Care: From Evidence to Healthcare Equity

HIV Updates for Pharmacy Practice

Maximizing Your Role to Impact Patient Outcomes

BRIDGE HCV

Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV

Case Challenges in HIV Medicine

Benefits, Barriers, & Best Practices in an Advancing Field

Challenges and Opportunities in HIV

Practical Solutions Across the Spectrum of Care